Chinese expert consensus on management of thrombocytopenia in cancer patients with liver injury (2022 edition)
10.3969/j.issn.1001-5256.2023.06.005
- VernacularTitle:肿瘤合并肝损伤患者血小板减少症管理中国专家共识(2022版)
- Publication Type:Guideline
- Keywords:
Cancer;
Liver Disease;
Liver Injury;
Thrombocytopenia;
Expert Consensus
- From:
Journal of Clinical Hepatology
2023;39(6):1287-1294
- CountryChina
- Language:Chinese
-
Abstract:
Thrombocytopenia and liver injury are common and serious clinical problems in cancer patients. The etiology of thrombocytopenia in cancer patients with liver injury (TCLI) is complicated, which is common in liver injury and tumor treatment. The management of cancer therapy-induced thrombocytopenia has gradually become standardized, and the management of liver injury-associated thrombocytopenia is becoming clear with the approval and marketing of relevant drugs. However, the management of TCLI is still blank, and the superposition of thrombocytopenia and liver injury further increases the difficulty of cancer treatment. Therefore, the Committee of Neoplastic Supportive-care, China Anti-Cancer Association organizes experts to analyze and discuss relevant literatures to form a Chinese expert consensus on the management of thrombocytopenia in cancer patients with liver injury (2022 Edition) to guide clinical practice.
